PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin
complex 1 (mTORC1) signaling pathways are frequently activated in acute myelogenous …
complex 1 (mTORC1) signaling pathways are frequently activated in acute myelogenous …
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
J Tamburini, N Chapuis, V Bardet… - Blood, The Journal …, 2008 - ashpublications.org
The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently
activated, representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 …
activated, representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 …
[HTML][HTML] Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia …
AM Martelli, F Chiarini, C Evangelisti, A Cappellini… - Oncotarget, 2012 - ncbi.nlm.nih.gov
Abstract Phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR)
are two key components of the PI3K/Akt/mTOR signaling pathway. This signal transduction …
are two key components of the PI3K/Akt/mTOR signaling pathway. This signal transduction …
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside
AM Martelli, PL Tazzari, C Evangelisti… - Current medicinal …, 2007 - ingentaconnect.com
The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB)/mammalian Target Of
Rapamycin (mTOR) signaling pathway plays a critical role in many cellular functions which …
Rapamycin (mTOR) signaling pathway plays a critical role in many cellular functions which …
mTOR regulates cell survival after etoposide treatment in primary AML cells
Q Xu, JE Thompson, M Carroll - Blood, 2005 - ashpublications.org
Acute myeloid leukemia cells have constitutive activation of phosphatidylinositol 3 (PI3)
kinase and require PI3 kinase activation for survival; however, the function of the PI3 kinase …
kinase and require PI3 kinase activation for survival; however, the function of the PI3 kinase …
Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
L Herschbein, JL Liesveld - Blood reviews, 2018 - Elsevier
The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin
(PI3K/Akt/mTOR) pathway is amplified in 60–80% of patients with acute myelogenous …
(PI3K/Akt/mTOR) pathway is amplified in 60–80% of patients with acute myelogenous …
[HTML][HTML] The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
AM Martelli, C Evangelisti, F Chiarini, JA McCubrey - Oncotarget, 2010 - ncbi.nlm.nih.gov
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling axis plays a central role in cell proliferation, growth, and survival under …
(mTOR) signaling axis plays a central role in cell proliferation, growth, and survival under …
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
AM Martelli, C Evangelisti, F Chiarini… - Expert opinion on …, 2009 - Taylor & Francis
Background: The PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays
a central role in cell growth, proliferation and survival not only under physiological …
a central role in cell growth, proliferation and survival not only under physiological …
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia
N Chapuis, J Tamburini, AS Green, C Vignon… - Clinical Cancer …, 2010 - AACR
Purpose: The growth and survival of acute myeloid leukemia (AML) cells are enhanced by
the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and …
the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and …
[HTML][HTML] A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream
effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute …
effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute …